 WESTLAKE VILLAGE, Calif., July 01, 2021 GLOBE NEWSWIRE -- Arcutis Biotherapeutics, Inc. Nasdaq: ARQT, today announced its decision to terminate the recently initiated Phase 2a clinical trial evaluating ARQ-252, a topical small molecule inhibitor of Janus kinase type 1 JAK1, as a potential treatment for vitiligo ARQ-252-213. Arcutis decision is based on further analyses of the ARQ-252 drug formulation used in both this vitiligo study and the recently completed Phase 2b study evaluating ARQ-252 for the treatment of chronic hand eczema ARQ-252-205. 